Opsens Inc. (TSE:OPS – Get Rating) – Research analysts at Raymond James issued their Q1 2024 earnings per share (EPS) estimates for shares of Opsens in a research report issued to clients and investors on Tuesday, November 22nd. Raymond James analyst R. Sarugaser forecasts that the company will post earnings of ($0.02) per share for the quarter. Raymond James currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Opsens’ current full-year earnings is ($0.07) per share. Raymond James also issued estimates for Opsens’ Q2 2024 earnings at ($0.02) EPS, Q3 2024 earnings at ($0.02) EPS, Q4 2024 earnings at ($0.01) EPS and FY2027 earnings at $0.19 EPS.
Opsens Stock Up 1.5 %
OPS stock opened at C$2.04 on Thursday. The company has a current ratio of 5.87, a quick ratio of 4.88 and a debt-to-equity ratio of 18.46. The firm has a market capitalization of C$221.89 million and a PE ratio of -34.58. Opsens has a 1-year low of C$1.55 and a 1-year high of C$3.74. The business’s 50 day simple moving average is C$2.45 and its 200 day simple moving average is C$2.39.
Opsens Company Profile
Opsens Inc develops, manufactures, installs, and sells fiber optic sensors for interventional cardiology, fractional flow reserve (FFR), oil and gas, and industrial applications. The company operates in two segments, Medical and Industrial. The Medical segment primarily focuses on physiological measurement, such as FFR and dPR in the coronary artery stenosis market; and supplies a range of miniature optical sensors to measure pressure and temperature used in integrated applications in other medical devices, as well as licenses its optical sensor technology.
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Opsens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opsens and related companies with MarketBeat.com's FREE daily email newsletter.